EHC · Encompass Health Corp
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 1, 2022; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Employees per occupied bed | 3.34 | the three months ended June 30, 2026 filing | — |
| Number of Common Shares Outstanding | 98.8M | Three Months Ended June 30, 2026 filing | — |
| # of licensed beds | 11,641 | Q2 2026 | — |
|
|
|||
| Adjusted earnings per share non-GAAP | $3.15 | Six Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Diluted earnings per share, as reported $3.32
-$0.05 Income tax adjustments(6)
+$0.02 Loss on early extinguishment of debt(7)
-$0.02 Change in fair market value of marketable securities
-$0.13 Gain on sale(4)
= Adjusted earnings per share $3.15
|
|||
| Adjusted EBITDA non-GAAP | $696.8M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted free cash flow non-GAAP | $370.8M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Average length of stay | 11.9 | Q2 2026 | — |
|
|
|||
| Contract labor FTEs | 333 | Q2 2026 | — |
|
|
|||
| Discharges | 68,895 | Q2 2026 | — |
|
|
|||
| EPOB | 3.34 | Q2 2026 | — |
|
|
|||
| Full-time equivalents (FTEs) - internal | 29,800 | Q2 2026 | — |
|
|
|||
| Net patient revenue per discharge | $22,521 | Q2 2026 | — |
|
|
|||
| New-store discharge growth | 2.8% | Q2 | — |
|
|
|||
| Occupancy % | 77.4% | Q2 2026 | — |
|
|
|||
| Occupied beds | 9,010 | Q2 2026 | — |
|
|
|||
| Outpatient visits | 21,742 | Q2 2026 | — |
|
|
|||
| Patient discharges (trailing four quarters) | 269,700 | trailing four quarters as of 06/30/26 | — |
| Rehabilitation hospitals (IRFs) | 176 | Company profile as of 06/30/26 | — |
| Revenue reserves related to bad debt as a percent of revenue | 2.3% | Q2 | — |
|
|
|||
| Same-store discharge growth | 2.8% | Q2 2026 | — |
|
|
|||
| Total discharge growth by quarter | 5.6% | Q2 2026 | — |
| Total FTEs | 30,133 | Q2 2026 | — |
|
|
|||
| Rehabilitation hospitals | 174 | as of 03/31/26 | — |
| Beds added to existing hospitals | 127 | Full Year 2025 | — |
| Hospitals (national footprint) | 173 | 2025 | — |
| Inpatient rehabilitation beds added | 517 | 2025 | — |
| IRFs under development | 16 | as of February 5, 2026 | — |
| Licensed beds | 11,465 | Q4 2025 | — |
| Net pre-opening and ramp up costs | $13.9M | Full Year 2025 | — |
| Number of consolidated hospitals | 173 | Q4 | — |
| Patient discharges | 263,299 | Full Year 2025 | — |
| Remaining common stock repurchase authorization | $332M | Full Year | — |
| Shares repurchased | 1,465,233 | Full Year 2025 | — |
| Total discharge growth | 6% | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EHC
this stock
Encompass Health Corp
|
$11.80B | +13.9% | +10.5% | 19.5 | 3.3% |
|
HCA
HCA Healthcare, Inc.
|
$93.03B | -10.5% | +7.1% | 14.5 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.21B | -6.9% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.48B | +34.3% | +0.9% | 10.3 | 3.1% |
|
FMS
Fresenius Medical Care AG
|
$12.38B | -3.0% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 1, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EHC | +0.5% | +8.8% | +11.3% | +8.8% | +13.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | 0.0% | +5.8% | -2.2% | +5.8% | +1.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.